Quantcast
Home > Quotes > AGIO

Agios Pharmaceuticals, Inc. Common Stock (AGIO) Quote & Summary Data

AGIO 
$85.94
*  
0.65
0.76%
Get AGIO Alerts
*Delayed - data as of May 22, 2018  -  Find a broker to begin trading AGIO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AGIO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
90
Today's High / Low
$ 87.29 / $ 84.70
Share Volume
275,776
50 Day Avg. Daily Volume
373,440
Previous Close
$ 85.29
52 Week High / Low
$ 89.33 / $ 45.96
Market Cap
4,950,627,069
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -6.81
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.51

Intraday Chart

Shares Traded

Share Volume:
275,776
50 Day Avg. Daily Volume:
373,440

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -6.81

Trading Range

The current last sale of $85.94 is 86.99% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 87.29 $ 89.33
 Low: $ 84.70 $ 45.96

Company Description (as filed with the SEC)

We are a biopharmaceutical company committed to the fundamental transformation of patients' lives through scientific leadership in the fields of cancer and rare genetic metabolic disorders. We have built a unique set of core capabilities in the field of cellular metabolism, with the goal of making transformative, first- or best-in-class medicines. Our therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a broad group of more than 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. In both of these areas, we are seeking to unlock the biology of cellular metabolism as a platform to create transformative therapies. Our most advanced cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.  ... More ...  

Risk Grade

Where does AGIO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 85.35
Open Date:
May 22, 2018
Close Price:
$ 85.94
Close Date:
May 22, 2018

Consensus Recommendation

Analyst Info